Trial Profile
Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 08 Mar 2022
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary)
- Indications Ascites; Hyponatraemia
- Focus Pharmacodynamics
- Sponsors Korea Otsuka Pharmaceutical
- 17 Feb 2022 Status changed from recruiting to discontinued.
- 10 Apr 2015 New trial record